---
title: "Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284829118.md"
description: "Helus Pharma's Interim CEO, Eric So, will present at the 29th Milken Global Conference on May 4, focusing on mental health innovation. The session will be available on the company's investor relations site, highlighting Helus Pharma's contributions to emerging mental health therapies. The latest analyst rating for Helus Pharma (HELP) stock is a Buy, with a price target of $95. The company is developing novel serotonergic agonists to address major mental health issues, including depression and anxiety, with ongoing clinical trials for its candidates."
datetime: "2026-04-30T20:17:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284829118.md)
  - [en](https://longbridge.com/en/news/284829118.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284829118.md)
---

# Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An announcement from Helus Pharma ( (HELP) ) is now available.

On April 30, 2026, Helus Pharma announced that Interim CEO Eric So will speak at the 29th Annual Milken Institute Global Conference in Los Angeles, appearing on a May 4 panel titled “The Next Wave of Health Innovation.” The live session and archived webcast will be accessible via the company’s investor relations site, offering investors and industry observers additional visibility into Helus Pharma’s role in emerging mental health therapies.

The most recent analyst rating on (HELP) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Helus Pharma stock, see the HELP Stock Forecast page.

**More about Helus Pharma**

Helus Pharma, the commercial name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Operating in Canada, the United States, the United Kingdom and Ireland, the company targets large unmet needs in depression, anxiety and other mental health conditions through candidates such as HLP003 in Phase 3 for major depressive disorder and HLP004 in Phase 2 for generalized anxiety disorder.

**Average Trading Volume:** 1,160,250

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $1.4M

See more data about HELP stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways](https://longbridge.com/en/news/283408643.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)
- [Watch live: Rethinking Psychedelic Treatment for America's Mental Health Crisis](https://longbridge.com/en/news/286901819.md)
- [Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | AVAI Stock News](https://longbridge.com/en/news/287067719.md)
- [VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO](https://longbridge.com/en/news/286643939.md)